Testing everolimus and epoetin for liver transplant tolerance
Treatments studied
Part of Digestive system clinical trials.
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 and 10 years after a liver transplant
- You take tacrolimus and do not take steroids as part of your anti-rejection medicines
- You do not have autoimmune liver disease or a history of recent rejection
- You have good kidney function (eGFR at least 40) and normal liver enzyme levels
- You are up to date on vaccinations and have no active infections (like TB, HIV, or hepatitis)
- You are not pregnant, do not use estrogen-based birth control, and have no history of blood clots or certain genetic disorders
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding everolimus can allow liver transplant recipients to safely reduce their usual immune-suppressing medicines. It aims to protect kidney function while preventing organ rejection.
This trial studies whether everolimus, a transplant medicine, can safely reduce the chance that liver cancer comes back after liver transplant. It compares how well the treatment works while carefully monitoring side effects and safety.
This trial tests a new combination of radiation and antibody treatment for people receiving a liver transplant at Stanford. The goal is to help your new liver last longer by training your immune system to accept it while reducing the need for lifelong anti-rejection drugs.
This trial tests if switching from a standard anti-rejection medicine to everolimus is safe and effective for liver transplant patients. It may help protect kidney function while preventing organ rejection.
This trial studies whether everolimus can improve outcomes for people whose kidney transplant biopsy shows signs of a specific type of immune attack. It focuses on patients without certain antibodies and with particular biopsy findings, aiming to prevent rejection-related injury while balancing medication side effects.
This trial tests a way to help your body accept your liver transplant without needing lifelong anti-rejection drugs. It uses your living donor's stem cells to train your immune system to not attack the new liver.
Hear when a new Liver Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.